

February 4, 2015

CymaBay to Present at 17th Annual BIO CEO & Investor Conference

NEWARK, CA -- (Marketwired) -- 02/04/15 -- CymaBay Therapeutics Inc.(NASDAQ: CBAY) announced today that Harold Van Wart, Ph.D., President and Chief Executive Officer, will present a corporate update at the 17th Annual BIO CEO & Investor Conference on Monday, February 9 at 2:30 p.m. Eastern Time. The conference will take place at the Waldorf Astoria in New York City. The presentation will be webcast live and available for replay for up to 30 days at <http://ir.cymbabay.com/events>.

About CymaBay

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat metabolic diseases with high unmet medical need, including serious rare and orphan disorders. Arhalofenate, the company's lead product candidate, has shown two therapeutic actions in a single drug in three prior Phase 2 gout studies. In gout patients, arhalofenate is intended to reduce painful flares in joints while at the same time promoting excretion of serum uric acid by the kidney, thereby addressing both the signs and symptoms of gout and the hyperuricemia that is the root cause of the disease. In addition to the studies described above, CymaBay has an ongoing 12-week Phase 2b clinical trial in patients with gout designed to detect significant reductions in gout flares. CymaBay's second product candidate, MBX-8025, is a potent and selective agonist of PPAR δ , a nuclear receptor important for lipid transport, storage and metabolism in liver and muscle. MBX-8025 has shown favorable effects on lipid and metabolic parameters in a Phase 2 study in patients with mixed dyslipidemia. Treatment effects observed include lowering of low density lipoprotein cholesterol (LDL-C) selective depletion of pro-atherogenic dense LDL-C particles, decreases in triglycerides and increases in high density lipoprotein, as well as decreases in high-sensitivity C-reactive protein, a biomarker of inflammation. CymaBay is in the process of initiating a pilot clinical study evaluating the activity of MBX-8025 in patients with homozygous familial hypercholesterolemia.

For additional information about CymaBay visit www.cymbabay.com.

Contacts:

Sujal Shah
CymaBay Therapeutics, Inc.
(510) 293-8800
sshah@cymbabay.com

Adam Cutler
The Trout Group, LLC
(646) 378-2936
CymaBay@troutgroup.com

Source: CymaBay Therapeutics